Clinical trial
Ropinirole XR (Extended Release) In Patients With Restless Legs Syndrome
NCT00197080 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00197080 |
|---|---|
| Title | Ropinirole XR (Extended Release) In Patients With Restless Legs Syndrome |
| Official title | A 12-Week, Double-Blind, Placebo Controlled, Parallel Group Study to Assess the Efficacy and Safety of Ropinirole XR (Extended Release) in Patients With Restless Legs Syndrome |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Restless Legs Syndrome |
| Intervention type | Drug |
| Interventions | Ropinirole Extended Release (XR) |
| Enrollment | 380 |
| Start date | Jun 1, 2005 |
| Completion | Jan 1, 2006 |
| First posted | Sep 20, 2005 |
| Last update posted | Sep 23, 2016 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: